Infecção por Sars-Cov-2 e o infarto agudo do miocárdio: revisão integrativa
DOI:
10.24276/rrecien2026.16.44065Palavras-chave:
Infarto do Miocárdio, COVID-19, SARS-CoV-2, Doenças CardiovascularesResumo
Analisar evidências científicas publicadas nos últimos cinco anos acerca da associação entre SARS-CoV-2 e infarto agudo do miocárdio. Trata-se de uma revisão integrativa realizada nas bases MEDLINE, LILACS, IBECS, BDENF e Coleciona SUS, incluindo artigos completos, gratuitos, publicados entre julho de 2020 e julho de 2025, em português, inglês e espanhol. A amostra final incluiu 14 estudos, que evidenciaram comprometimento cardiovascular por mecanismos fisiopatológicos inter-relacionados. Além disso, pacientes com ambas comorbidades apresentaram maior carga trombótica coronariana, elevação expressiva de biomarcadores de necrose miocárdica, inflamação e coagulação, apresentação clínica frequentemente atípica e mortalidade de quatro a sete vezes superior à observada em pacientes sem infecção. A subutilização de terapias de reperfusão e o aumento da incidência de choque cardiogênico também foram documentados de forma consistente. Em suma, há associação clinicamente significativa na coinfecção, reforçando a necessidade de protocolos assistenciais específicos, reconhecimento precoce, monitoramento cardiovascular e acesso oportuno à reperfusão.
Descritores: Infarto do Miocárdio, COVID-19, SARS-CoV-2, Doenças Cardiovasculares.
SARS-CoV-2 infection and acute myocardial infarction: an integrative review
Abstract: To analyze scientific evidence published in the last five years regarding the association between SARS-CoV-2 and acute myocardial infarction. This is an integrative review conducted in the MEDLINE, LILACS, IBECS, BDENF, and Coleciona SUS databases, including full-text, free-access articles published between July 2020 and July 2025 in Portuguese, English, and Spanish. The final sample included 14 studies, which showed cardiovascular involvement through interrelated pathophysiological mechanisms. In addition, patients with both conditions presented higher coronary thrombotic burden, marked elevation of biomarkers of myocardial necrosis, inflammation, and coagulation, frequently atypical clinical presentation, and mortality four to seven times higher than that observed in patients without infection. The underuse of reperfusion therapies and the increased incidence of cardiogenic shock were also consistently documented. In summary, there is a clinically significant association in coinfection, reinforcing the need for specific care protocols, early recognition, cardiovascular monitoring, and timely access to reperfusion.
Descriptors: Myocardial Infarction, COVID-19, SARS-CoV-2, Cardiovascular Diseases.
Infección por SARS-CoV-2 e infarto agudo de miocardio: revisión integrativa
Resumen: Analizar la evidencia científica publicada en los últimos cinco años acerca de la asociación entre SARS-CoV-2 e infarto agudo de miocardio. Se trata de una revisión integradora realizada en las bases de datos MEDLINE, LILACS, IBECS, BDENF y Coleciona SUS, que incluyó artículos completos, gratuitos, publicados entre julio de 2020 y julio de 2025, en portugués, inglés y español. La muestra final incluyó 14 estudios, que evidenciaron compromiso cardiovascular mediante mecanismos fisiopatológicos interrelacionados. Además, los pacientes con ambas condiciones presentaron mayor carga trombótica coronaria, elevación expresiva de biomarcadores de necrosis miocárdica, inflamación y coagulación, presentación clínica frecuentemente atípica y mortalidad de cuatro a siete veces superior a la observada en pacientes sin infección. También se documentaron de forma consistente la subutilización de terapias de reperfusión y el aumento de la incidencia de choque cardiogénico. En síntesis, existe una asociación clínicamente significativa en la coinfección, lo que refuerza la necesidad de protocolos asistenciales específicos, reconocimiento precoz, monitorización cardiovascular y acceso oportuno a la reperfusión.
Descriptores: Infarto del Miocardio, COVID-19, SARS-CoV-2, Enfermedades Cardiovasculares.
Downloads
Referências
Brasil. Ministério da Saúde. Covid-19. Brasília: Ministério da Saúde. 2025. Disponível em: <https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/c/covid-19>. Acesso em 26 jun 2025.
Organização Pan-Americana da Saúde. Histórico da emergência internacional de COVID-19. Washington: OPAS. 2025. Disponível em: <https://www.paho.org/pt/historico-da-emergencia-internacional-covid-19>. Acesso em 26 jun 2025.
World Health Organization. COVID-19 deaths: WHO COVID-19 dashboard. Geneva: WHO. 2025. Disponível em: <https://data.who.int/dashboards/covid19/deaths?n=o>. Acesso em 26 jun 2025.
Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. 2020; 383(6):590-592.
Torabizadeh C, Iloonkashkooli R, Haghshenas H, Fararouei M. Prevalence of cardiovascular complications in coronavirus disease 2019 adult patients: a systematic review and meta-analysis. Iran J Med Sci. 2023; 48(2):123-137.
Zhao YH, Zhao L, Yang XC, Wang P. Cardiovascular complications of SARS-CoV-2 infection (COVID-19): a systematic review and meta-analysis. Rev Cardiovasc Med. 2021; 22(1):159-165.
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018; 72(18):2231-2264.
Brasil. Ministério da Saúde. Infarto. Brasília: Ministério da Saúde. 2025. Disponível em: <https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/i/infarto>. Acesso em 26 jun 2025.
Ho FK, Man KKC, Toshner M, Church C, Celis-Morales C, Wong ICK, et al. Thromboembolic risk in hospitalized and nonhospitalized COVID-19 patients: a self-controlled case series analysis of a nationwide cohort. Mayo Clin Proc. 2021; 96(10):2587-2597.
Alharbi A, Franz A, Alfatlawi H, Wazzan M, Alsughayer A, Eltahawy E, et al. Impact of COVID-19 pandemic on the outcomes of acute coronary syndrome. Curr Probl Cardiol. 2023; 48(4):101575.
Botelho LLR, Cunha CCA, Macedo M. O método da revisão integrativa nos estudos organizacionais. Gestão e Sociedade. 2011; 5(11):121-136.
Morgan RL, Whaley P, Thayer KA, Schünemann HJ. Identifying the PECO: a framework for formulating good questions to explore the association of environmental and other exposures with health outcomes. Environ Int. 2018; 121(Pt 1):1027-1031.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71.
Melnyk BM, Fineout-Overholt E. Evidence-based practice in nursing & healthcare: a guide to best practice. 4th ed. Philadelphia: Wolters Kluwer Health. 2018.
Arnold JR, Yeo JL, Budgeon CA, Shergill S, England R, Shiwani H, et al. Myocardial ischaemia following COVID-19: a cardiovascular magnetic resonance study. Int J Cardiovasc Imaging. 2025; 41:247-256.
Bhatt AS, Varshney AS, Goodrich EL, Gong J, Ginder C, Senman BC, et al. Epidemiology and management of ST-segment-elevation myocardial infarction in patients with COVID-19: a report from the American Heart Association COVID-19 Cardiovascular Disease Registry. J Am Heart Assoc. 2022; 11(12):e024353.
Case BC, Yerasi C, Forrestal BJ, Shea C, Rappaport H, Medranda GA, et al. Comparison of characteristics and outcomes of patients with acute myocardial infarction with versus without coronavirus-19. Am J Cardiol. 2021; 144:8-12.
Choudry FA, Hamshere SM, Rathod KS, Akhtar MM, Archbold RA, Guttmann OP, et al. High thrombus burden in patients with COVID-19 presenting with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2020; 76(10):1168-1176.
De Luca G, Debel N, Cercek M, Jensen LO, Vavlukis M, Calmac L, et al. Impact of SARS-CoV-2 positivity on clinical outcome among STEMI patients undergoing mechanical reperfusion: insights from the ISACS STEMI COVID-19 registry. Atherosclerosis. 2021; 332:48-54.
Kiris T, Avci E, Ekin T, Akgün DE, Tiryaki M, Yidirim A, et al. Impact of COVID-19 outbreak on patients with ST-segment elevation myocardial infarction in Turkey: results from TURSER study. J Thromb Thrombolysis. 2022; 53(2):321-334.
Kite TA, Ludman PF, Gale CP, Wu J, Caixeta A, Mansourati J, et al. International prospective registry of acute coronary syndromes in patients with COVID-19. J Am Coll Cardiol. 2021; 77(20):2466-2476.
Li Y, Yang D, Kang J, Cao Y, Cui L, Liu F. COVID-19 and the risk of acute cardiovascular diseases: a two-sample Mendelian randomization study. BMC Cardiovasc Disord. 2024; 24:389.
Little CD, Kotecha T, Candilio L, Jabbour RJ, Collins GB, Ahmed A, et al. COVID-19 pandemic and STEMI: pathway activation and outcomes from the pan-London heart attack group. Open Heart. 2020; 7(2):e001432.
Marfella R, Paolisso P, Sardu C, Palomba L, D'Onofrio N, Cesaro A, et al. SARS-CoV-2 colonizes coronary thrombus and impairs heart microcirculation bed in asymptomatic SARS-CoV-2 positive subjects with acute myocardial infarction. Crit Care. 2021; 25:217.
Matsushita K, Hess S, Marchandot B, Sato C, Truong DP, Kim NT. Clinical features of patients with acute coronary syndrome during the COVID-19 pandemic. J Thromb Thrombolysis. 2020; 52(1):95-104.
Neves APL, Machado MN, Gandolfi JV, Machado LF, Syrio JD, Luckmeyer G, et al. Myocardial injury and cardiovascular complications in COVID-19: a cohort study in severe and critical patients. Rev Bras Ter Intensiva. 2022; 34(4):443-451.
Rashid M, Wu J, Timmis A, Curzen N, Clarke S, Zaman A, et al. Clinical characteristics and outcomes of COVID-19-positive acute coronary syndrome patients: a multisource electronic healthcare records study from England. J Intern Med. 2021; 290(1):88-100.
Solano-López J, Zamorano JL, Pardo Sanz A, Amat-Santos I, Sarnago F, Gutiérrez Ibañes E, et al. Risk factors for in-hospital mortality in patients with acute myocardial infarction during the COVID-19 outbreak. Rev Esp Cardiol. 2020; 73(12):985-993.
Triantafyllis AS, Sfantou D, Karapedi E, Peteinaki K, Kotoulas SC, Saad R, et al. Coronary implications of COVID-19. Med Princ Pract. 2025; 34(1):1-12.
Chung MK, Zidar DA, Bristow MR, Cameron SJ, Chan T, Harding CV, et al. COVID-19 and cardiovascular disease: from bench to bedside. Circ Res. 2021; 128(8):1214-1236.
Publicado
- Visualizações 0
- pdf downloads: 0
Como Citar
Edição
Seção

Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.














